Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 49M | 13779.8% |
| Gross Profit | 38M | 396% |
| Cost of Revenue | 11M | 17% |
| Operating expense | 39M | 3.6% |
| Net Income | 11M | 129.5% |
| EBITDA | 11M | 131.8% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 111M | 19.6% |
| Total Liabilities | 72M | 4% |
| Total Equity | 39M | 65.2% |
| Shares Outstanding | 208M | 2.2% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 12M | 143.7% |
| Cash from investing | 230,000 | 83.5% |
| Cash from financing | -200,000 | 61.9% |
EPS
Financial Highlights for Sangamo Therapeutics in Q3 '24
Sangamo Therapeutics reported a revenue of 49M, which is a 13779.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 38M, marking a 396% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 11M, a -17% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 39M, showing a 3.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 11M, showing a 129.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 11M, showing a 131.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Sangamo Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
